Clinical trial · Observational
Anlotinib for Esophageal Cancer (AFEC)
A Real World Study on the Effect of Single or Combined Treatment of Anlotinib on Survival and Prognosis of Advanced Esophageal Cancer
NCT04966611CI-TRIAL-00052762unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to observe and explore the effect of single or combined treatment of arotinib on the survival and prognosis of patients with advanced esophageal cancer in the real world, and to summarize the treatment experience of a wide range of people.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anlotinib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- OS
- timeFrame
- From date of admission until the date of death from any cause, assessed up to 24 months
- description
- Overall Survival
Secondary outcomes (1)
- measure
- PFS
- timeFrame
- From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
- description
- Progression Free Survival
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Age: ≥ 18 years old, male or female; 2. Patients with esophageal cancer were diagnosed; 3. Patients assessed by doctors to benefit from single or combined treatment of arotinib; 4. Patients volunteered to join the project. Exclusion Criteria: None
References
Publications (0)
Data not yet available
No reference posted for this study.